Tumoral reprogramming: Plasticity takes a walk on the wild side

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1849, Issue 4, 2015, Pages 436-447

  Campos Sánchez, Elena ^a   Cobaleda, César ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Cancer reprogramming; Cancer stem cells; Induced pluripotency; IPSCs; Plasticity

Indexed keywords

CANCER CELL; CANCER REPROGRAMMING; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; HUMAN; NONHUMAN; NUCLEAR REPROGRAMMING; PLASTICITY; PRIORITY JOURNAL; REVIEW; TISSUE REGENERATION; ANIMAL; CELL DEDIFFERENTIATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PLURIPOTENT STEM CELL; REGENERATION;

ANIMALS; CELL DEDIFFERENTIATION; CELLULAR REPROGRAMMING; GROWTH AND DEVELOPMENT; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NEOPLASMS; NEOPLASTIC STEM CELLS; REGENERATION;

EID: 85027940061     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.07.003     Document Type: Review

References (174)

1. Graf T., Enver T. Forcing cells to change lineages. Nature 2009, 462(7273):587-594.
2. Gurdon J.B., Melton D.A. Nuclear reprogramming in cells. Science 2008, 322(5909):1811-1815.
3. Hochedlinger K., Jaenisch R. Nuclear reprogramming and pluripotency. Nature 2006, 441(7097):1061-1067.
4. Sanchez Alvarado A., Yamanaka S. Rethinking differentiation: stem cells, regeneration, and plasticity. Cell 2014, 157(1):110-119.
5. Vicente-Duenas C., et al. The role of cellular plasticity in cancer development. Curr. Med. Chem. 2009, 16(28):3676-3685.
6. Hochedlinger K., Plath K. Epigenetic reprogramming and induced pluripotency. Development 2009, 136(4):509-523.
7. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14(3):275-291.
8. Waddington C.H. The Strategy of the Genes 1957, Ruskin House, London, (London). A. Unwin (Ed.).
9. Enver T., et al. Stem cell states, fates, and the rules of attraction. Cell Stem Cell 2009, 4(5):387-397.
10. Huang S. Reprogramming cell fates: reconciling rarity with robustness. Bioessays 2009, 31(5):546-560.
11. Huang S., Ernberg I., Kauffman S. Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Semin. Cell Dev. Biol. 2009, 20(7):869-876.
12. Hall C.J., et al. Infection-responsive expansion of the hematopoietic stem and progenitor cell compartment in zebrafish is dependent upon inducible nitric oxide. Cell Stem Cell 2012, 10(2):198-209.
13. Iglesias-Bartolome R., et al. mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell 2012, 11(3):401-414.
14. Shi C., et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity 2011, 34(4):590-601.
15. Zhao J.L., et al. Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis. Cell Stem Cell 2014, 14(4):445-459.
16. Vicente-Duenas C., et al. Function of oncogenes in cancer development: a changing paradigm. EMBO J. 2013, 32(11):1502-1513.
17. Buczacki S.J., et al. Intestinal label-retaining cells are secretory precursors expressing Lgr5. Nature 2013, 495(7439):65-69.
18. Clevers H. Stem cells: a unifying theory for the crypt. Nature 2013, 495(7439):53-54.
19. Doupe D.P., et al. A single progenitor population switches behavior to maintain and repair esophageal epithelium. Science 2012, 337(6098):1091-1093.
20. Davis R.L., Weintraub H., Lassar A.B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987, 51(6):987-1000.
21. Cobaleda C., Busslinger M. Developmental plasticity of lymphocytes. Curr. Opin. Immunol. 2008, 20(2):139-148.
22. Cobaleda C., Jochum W., Busslinger M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 2007, 449(7161):473-477.
23. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676.
24. Briggs R., King T.J. Transplantation of living nuclei from blastula cells into enucleated frogs' eggs. Proc. Natl. Acad. Sci. U. S. A. 1952, 38(5):455-463.
25. Gurdon J.B. The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J. Embryol. Exp. Morpholog. 1962, 10:622-640.
26. Sanchez-Garcia I. Getting to the stem of cancer. Semin. Cancer Biol. 2010, 20(2):63-64.
27. Hamburger A., Salmon S.E. Primary bioassay of human myeloma stem cells. J. Clin. Invest. 1977, 60(4):846-854.
28. Chen J., et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488(7412):522-526.
29. Driessens G., et al. Defining the mode of tumour growth by clonal analysis. Nature 2012, 488(7412):527-530.
30. Kirk R. Tumour evolution: evidence points to the existence of cancer stem cells. Nat. Rev. Clin. Oncol. 2012, 9(10):552.
31. Schepers A.G., et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012, 337(6095):730-735.
32. Perez-Caro M., et al. Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J. 2009, 28(1):8-20.
33. Vicente-Duenas C., et al. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(26):10534-10539.
34. Cobaleda C., Sanchez-Garcia I. B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin. Bioessays 2009, 31(6):600-609.
35. Lobo N.A., et al. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 2007, 23:675-699.
36. Sanchez-Garcia I., Vicente-Duenas C., Cobaleda C. The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice?. Bioessays 2007, 29(12):1269-1280.
37. Vicente-Duenas C., et al. Stem-cell driven cancer: "hands-off" regulation of cancer development. Cell Cycle 2009, 8(9):1314-1318.
38. Crews L.A., Jamieson C.H. Selective elimination of leukemia stem cells: hitting a moving target. Cancer Lett. 2013, 338(1):15-22.
39. Guzman M.L., Allan J.N. Concise review: leukemia stem cells in personalized medicine. Stem Cells 2014, 32(4):844-851.
40. Medema J.P. Cancer stem cells: the challenges ahead. Nat. Cell Biol. 2013, 15(4):338-344.
41. Vidal S.J., et al. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2013 Oct 7, [Epub ahead of print]. 10.1038/onc.2013.411.
42. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
43. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
44. Xie H., et al. Stepwise reprogramming of B cells into macrophages. Cell 2004, 117(5):663-676.
45. Chen Y., et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J. Biol. Chem. 2008, 283(26):17969-17978.
46. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448(7151):313-317.
47. Rowland B.D., Bernards R., Peeper D.S. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell Biol. 2005, 7(11):1074-1082.
48. Tanaka Y., et al. Forced expression of Nanog in hematopoietic stem cells results in a gammadeltaT-cell disorder. Blood 2007, 110(1):107-115.
49. Sridharan R., et al. Role of the murine reprogramming factors in the induction of pluripotency. Cell 2009, 136(2):364-377.
50. Huangfu D., et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat. Biotechnol. 2008, 26(7):795-797.
51. Huangfu D., et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat. Biotechnol. 2008, 26(11):1269-1275.
52. Nakagawa M., et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 2008, 26(1):101-106.
53. Wernig M., et al. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2008, 2(1):10-12.
54. Boyer L.A., et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122(6):947-956.
55. Loh Y.H., et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat. Genet. 2006, 38(4):431-440.
56. Hanna J., et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 2008, 133(2):250-264.
57. Hu J., et al. From the cover: neutralization of terminal differentiation in gliomagenesis. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(36):14520-14527.
58. Ting A.H., McGarvey K.M., Baylin S.B. The cancer epigenome-components and functional correlates. Genes Dev. 2006, 20(23):3215-3231.
59. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8(4):286-298.
60. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358(11):1148-1159.
61. Esteller M., Herman J.G. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J. Pathol. 2002, 196(1):1-7.
62. Mikkelsen T.S., et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008, 454(7200):49-55.
63. Feldman N., et al. G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat. Cell Biol. 2006, 8(2):188-194.
64. Epsztejn-Litman S., et al. De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes. Nat. Struct. Mol. Biol. 2008, 15(11):1176-1183.
65. Banito A., et al. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev. 2009, 23(18):2134-2139.
66. Hong H., et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009, 460(7259):1132-1135.
67. Kawamura T., et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460(7259):1140-1144.
68. Krizhanovsky V., Lowe S.W. Stem cells: the promises and perils of p53. Nature 2009, 460(7259):1085-1086.
69. Li H., et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009, 460(7259):1136-1139.
70. Marion R.M., et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460(7259):1149-1153.
71. Utikal J., et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009, 460(7259):1145-1148.
72. Zhao Y., et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 2008, 3(5):475-479.
73. Vicente-Duenas C., et al. Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB. Cell Cycle 2012, 11(20):3896-3900.
74. Vicente-Duenas C., et al. A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J. 2012, 31(18):3704-3717.
75. Velasco-Hernandez T., et al. p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice. Cell Cycle 2013, 12(1):122-132.
76. Abad M., et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature 2013, 502(7471):340-345.
77. Hobbs R.M., Polo J.M. Reprogramming can be a transforming experience. Cell Stem Cell 2014, 14(3):269-271.
78. Ohnishi K., et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 2014, 156(4):663-677.
79. Ryan B.M., Robles A.I., Harris C.C. Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer 2010, 10(6):389-402.
80. Kasinski A.L., Slack F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11(12):849-864.
81. Fabbri M., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(40):15805-15810.
82. Friedman J.M., et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 2009, 69(6):2623-2629.
83. Varambally S., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322(5908):1695-1699.
84. Saito Y., et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9(6):435-443.
85. Lee B., et al. Transcriptional mechanisms link epithelial plasticity to adhesion and differentiation of epidermal progenitor cells. Dev. Cell 2014, 29(1):47-58.
86. Li S., Yang J. Ovol proteins: guardians against EMT during epithelial differentiation. Dev. Cell 2014, 29(1):1-2.
87. Nieto M.A. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 2013, 342(6159):1234850.
88. Watanabe K., et al. Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor. Dev. Cell 2014, 29(1):59-74.
89. Vicente-Duenas C., et al. The role of cellular plasticity in cancer development. Curr. Med. Chem. 2009, 16(28):3676-3685.
90. Melo J.V., Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 2007, 7(6):441-453.
91. Corces-Zimmerman M.R., et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(7):2548-2553.
92. Welch J.S., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150(2):264-278.
93. Walker B.A., et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 2013, 121(17):3413-3419.
94. Castellanos A., et al. Cancer as a reprogramming-like disease: implications in tumor development and treatment. Semin. Cancer Biol. 2010, 20(2):93-97.
95. Vicente-Duenas C., et al. The evolution of cancer modeling: the shadow of stem cells. Dis. Models Mech. 2010, 3(3-4):149-155.
96. Vicente-Duenas C., et al. The cellular architecture of multiple myeloma. Cell Cycle 2012, 11(20):3715-3717.
97. Shin K., et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat. Cell Biol. 2014, 16(5):469-478.
98. Westphalen C.B., et al. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. J. Clin. Invest. 2014, 124(3):1283-1295.
99. Barker N., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457(7229):608-611.
100. Zhu L., et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457(7229):603-607.
101. Mainardi S., et al. Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(1):255-260.
102. Alcantara Llaguno S., et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009, 15(1):45-56.
103. Dirks P.B. Cancer's source in the peripheral nervous system. Nat. Med. 2008, 14(4):373-375.
104. Joseph N.M., et al. The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell 2008, 13(2):129-140.
105. Zheng H., et al. Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell 2008, 13(2):117-128.
106. Straessler K.M., et al. Modeling clear cell sarcomagenesis in the mouse: cell of origin differentiation state impacts tumor characteristics. Cancer Cell 2013, 23(2):215-227.
107. Mitelman F., Johansson B., Mertens F. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer 2013.
108. Huntly B.J., et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004, 6(6):587-596.
109. Krivtsov A.V., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442(7104):818-822.
110. Somervaille T.C., Cleary M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006, 10(4):257-268.
111. Cozzio A., et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003, 17(24):3029-3035.
112. So C.W., et al. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 2003, 3(2):161-171.
113. Guibal F.C., et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood 2009, 114(27):5415-5425.
114. Wojiski S., et al. PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia 2009, 23(8):1462-1471.
115. Wong D.J., et al. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2(4):333-344.
116. Chen L., et al. Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS ONE 2007, 2:e293.
117. Schwitalla S., et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013, 152(1-2):25-38.
118. Krivtsov A.V., et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia 2013, 27(4):852-860.
119. Wang Z.A., et al. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat. Cell Biol. 2013, 15(3):274-283.
120. Johnson B.E., et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014, 343(6167):189-193.
121. Baca S.C., et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153(3):666-677.
122. Humphries A., et al. Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(27):E2490-E2499.
123. Klco J.M., et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014, 25(3):379-392.
124. Blackburn J.S., et al. Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell 2014, 25(3):366-378.
125. Hong D., et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008, 319(5861):336-339.
126. Miyamoto T., Weissman I.L., Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(13):7521-7526.
127. le Viseur C., et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008, 14(1):47-58.
128. Mullighan C.G., et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322(5906):1377-1380.
129. Barabe F., et al. Modeling the initiation and progression of human acute leukemia in mice. Science 2007, 316(5824):600-604.
130. Papp B., Plath K. Epigenetics of reprogramming to induced pluripotency. Cell 2013, 152(6):1324-1343.
131. Barnes D.J., Melo J.V. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006, 5(24):2862-2866.
132. Graham S.M., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99(1):319-325.
133. Pellicano F., Mukherjee L., Holyoake T.L. Cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting. Stem Cells 2014, 32(6):1373-1379.
134. Walkley C.R., et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007, 129(6):1097-1110.
135. Raaijmakers M.H., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464(7290):852-857.
136. Walkley C.R., et al. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 2007, 129(6):1081-1095.
137. Duan C.W., et al. Leukemia propagating cells rebuild an evolving niche in response to therapy. Cancer Cell 2014, 25(6):778-793.
138. Cao Z., et al. Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer Cell 2014, 25(3):350-365.
139. Schepers K., et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 2013, 13(3):285-299.
140. Arranz L., et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature 2014, 10.1038/nature13383.
141. Medyouf H., et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 2014, 14(6):824-837.
142. Barcellos-Hoff M.H., Lyden D., Wang T.C. The evolution of the cancer niche during multistage carcinogenesis. Nat. Rev. Cancer 2013, 13(7):511-518.
143. Miething C., et al. PTEN action in leukaemia dictated by the tissue microenvironment. Nature 2014, 509(7505):402-406.
144. Krause D.S., et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat. Med. 2013, 19(11):1513-1517.
145. Zhang B., et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 2012, 21(4):577-592.
146. Wiseman D.H. Donor cell leukemia: a review. Biol. Blood Marrow Transplant 2011, 17(6):771-789.
147. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147(5):992-1009.
148. Oskarsson T., Batlle E., Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 2014, 14(3):306-321.
149. Chabner B.A., Roberts T.G. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 2005, 5(1):65-72.
150. Frangioni J.V. New technologies for human cancer imaging. J. Clin. Oncol. 2008, 26(24):4012-4021.
151. Marder J. Cancer research. Childhood's cures haunted by adulthood's 'late effects'. Science 2010, 328(5985):1474-1475.
152. Abollo-Jimenez F., et al. Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis. Cell Cycle 2014, 13(11).
153. Hochedlinger K., et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 2004, 18(15):1875-1885.
154. Blelloch R.H., et al. Nuclear cloning of embryonal carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(39):13985-13990.
155. Li L., et al. Mouse embryos cloned from brain tumors. Cancer Res. 2003, 63(11):2733-2736.
156. Han X., et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat. Commun. 2014, 5:3261.
157. Gupta P.B., et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 146(4):633-644.
158. Roesch A., et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141(4):583-594.
159. Sharma S.V., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141(1):69-80.
160. Chaffer C.L., et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013, 154(1):61-74.
161. Harrison C. Anticancer drugs: reprogramming metabolism in lung cancer. Nat. Rev. Drug Discov. 2014, 13(6):418.
162. Stricker S., Pollard S. Reprogramming cancer cells to pluripotency: an experimental tool for exploring cancer epigenetics. Epigenetics 2014, 9(6).
163. Stricker S.H., et al. Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Dev. 2013, 27(6):654-669.
164. Zhang X., et al. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 2013, 32(18):2249-2260. (2260 e1-21).
165. Liu Y., et al. Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells. Leukemia 2014, 28(5):1071-1080.
166. Bhatla T., et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 2012, 119(22):5201-5210.
167. Mack S.C., et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 2014, 506(7489):445-450.
168. Kaminskas E., et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 2005, 11(10):3604-3608.
169. Dey P. Chromatin remodeling, cancer and chemotherapy. Curr. Med. Chem. 2006, 13(24):2909-2919.
170. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27(32):5459-5468.
171. Campos-Sanchez E., et al. Current concepts of how to eliminate cancer stem cells. Role of Cancer Stem Cells in Cancer Biology and Therapy 2013, 167-198. CRC Press.
172. Pattabiraman D.R., Weinberg R.A. Tackling the cancer stem cells-what challenges do they pose?. Nat. Rev. Drug Discov. 2014, 13(7):497-512.
173. Tai Y.T., et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012, 120(9):1877-1887.
174. Schmidt T., et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 2011, 19(6):740-753.